Cholestasis and Metabolic Bone Disease - a Clinical Review

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2008 Nov 11

PMID 18998071

Citations 20

Authors

Rudolf W Gasser

Affiliations

Soon will be listed here.

Abstract

Metabolic bone disease, mainly osteopenia/osteoporosis and occasionally osteomalacia, is a major extrahepatic manifestation of chronic cholestatic liver disease (synonym: hepatic osteodystrophy). Reduced bone mineral density is found in up to 60% and atraumatic fractures in about 20% of patients with chronic liver disease. Hepatic osteodystrophy is characterized by reduced formation and increased resorption of bone; major risk factors are chronic cholestasis and advanced cirrhosis. Pathogenetic mechanisms include genetic factors, abnormalities of calcium, vitamin D, vitamin K and bilirubin metabolism, IGF-1 deficiency, the RANKL/OPG-system, hypogonadism, drugs harmful to bone, lifestyle factors (smoking, alcoholism, immobility), malnutrition and low body mass index. Screening for osteopenia should be performed and reversible risk factors must be corrected. At present, bisphosphonates are the predominantly used specific drugs for the treatment of osteoporosis in chronic liver disease. After orthotopic liver transplantation bone mineral density improves in long-term follow-up. Studies are needed for fracture prevention in chronic liver disease.

Citing Articles

A Quality Improvement Project to Decrease Fractures Secondary to Metabolic Bone Disease of Prematurity.

Rau N, Monagle L, Fischer A Pediatr Qual Saf. 2024; 9(4):e750.

PMID: 39077117 PMC: 11286248. DOI: 10.1097/pq9.0000000000000750.

Investigation of the influential factors for hepatic osteodystrophy in chronic liver disease: A case-control survey among the patients attending a tertiary care hospital in a rural region of Northern India.

Yadav E, Kaur R, Sasan A, Garg S Tzu Chi Med J. 2023; 35(1):95-102.

PMID: 36866351 PMC: 9972938. DOI: 10.4103/tcmj.tcmj_27_22.

Osteoporosis Assessment among Adults with Liver Cirrhosis.

Ionele C, Turcu-Stiolica A, Subtirelu M, Ungureanu B, Sas T, Rogoveanu I J Clin Med. 2023; 12(1).

PMID: 36614954 PMC: 9820827. DOI: 10.3390/jcm12010153.

A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis.

Ionele C, Turcu-Stiolica A, Subtirelu M, Ungureanu B, Cioroianu G, Rogoveanu I J Clin Med. 2022; 11(13).

PMID: 35807091 PMC: 9267321. DOI: 10.3390/jcm11133807.

The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article.

Stremmel W, Lukasova M, Weiskirchen R Ann Transl Med. 2021; 9(8):738.

PMID: 33987436 PMC: 8106090. DOI: 10.21037/atm-20-3591.

References

Maalouf N, Sakhaee K . Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients. Curr Treat Options Gastroenterol. 2006; 9(6):456-63. DOI: 10.1007/s11938-006-0002-y. View

Matloff D, KAPLAN M, Neer R, Goldberg M, Bitman W, WOLFE H . Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology. 1982; 83(1 Pt 1):97-102. View

Weinreb M, Pollak R, Ackerman Z . Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis. J Hepatol. 2004; 40(3):385-90. DOI: 10.1016/j.jhep.2003.11.032. View

Eileen Hay J, Guichelaar M . Evaluation and management of osteoporosis in liver disease. Clin Liver Dis. 2005; 9(4):747-66, viii. DOI: 10.1016/j.cld.2005.07.003. View

Eileen Hay J . Osteoporosis in liver diseases and after liver transplantation. J Hepatol. 2003; 38(6):856-65. DOI: 10.1016/s0168-8278(03)00143-0. View

Pusl T, Beuers U . Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005; 28(2):147-57. DOI: 10.1385/CRIAI:28:2:147. View

Janes C, Dickson E, Okazaki R, Bonde S, McDonagh A, Riggs B . Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995; 95(6):2581-6. PMC: 295940. DOI: 10.1172/JCI117959. View

Pereira S, ODonohue J, Moniz C, PHILLIPS M, Abraha H, Buxton-Thomas M . Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther. 2004; 19(5):563-70. DOI: 10.1111/j.1365-2036.2004.01890.x. View

Collier J, Ninkovic M, Compston J . Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002; 50 Suppl 1:i1-9. PMC: 1867644. DOI: 10.1136/gut.50.suppl_1.i1. View

10.

Ormarsdottir S, Mallmin H, Naessen T, Petren-Mallmin M, Broome U, Hultcrantz R . An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med. 2004; 256(1):63-9. DOI: 10.1111/j.1365-2796.2004.01342.x. View

11.

Hay J . Bone disease in cholestatic liver disease. Gastroenterology. 1995; 108(1):276-83. DOI: 10.1016/0016-5085(95)90033-0. View

12.

Guichelaar M, Malinchoc M, Sibonga J, Clarke B, Eileen Hay J . Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology. 2002; 36(4 Pt 1):895-903. DOI: 10.1053/jhep.2002.36357. View

13.

Pignata S, Daniele B, Galati M, Esposito G, Vallone P, Fiore F . Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1997; 9(3):283-6. DOI: 10.1097/00042737-199703000-00012. View

14.

Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T . Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol. 2001; 35(4):543-5. DOI: 10.1016/s0168-8278(01)00133-7. View

15.

Millonig G, Graziadei I, Eichler D, Pfeiffer K, Finkenstedt G, Muehllechner P . Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 2005; 11(8):960-6. DOI: 10.1002/lt.20466. View

16.

Moschen A, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P . The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005; 43(6):973-83. DOI: 10.1016/j.jhep.2005.05.034. View

17.

Kowdley K, Emond M, Sadowski J, KAPLAN M . Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol. 1997; 92(11):2059-61. View

18.

de Albuquerque Taveira A, Fernandes M, Galvao L, Sawamura R, de Mello Vieira E, de Paula F . Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol (Oxf). 2007; 66(4):518-23. DOI: 10.1111/j.1365-2265.2007.02765.x. View

19.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

20.

Boone R, Cheung A, Girlan L, Heathcote E . Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci. 2006; 51(6):1103-12. DOI: 10.1007/s10620-006-8015-x. View